Roche is­sues vol­un­tary re­call for Susvi­mo over man­u­fac­tur­ing is­sue

It’s been al­most a year since Roche’s block­buster oc­u­lar im­plant, the wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) drug Susvi­mo, was cleared for twice-an­nu­al ad­min­is­tra­tion as op­posed to month­ly in­jec­tions. Now the com­pa­ny is putting a hold on it.

In the Big Phar­ma’s Q3 in­vestor call, Roche Phar­ma­ceu­ti­cals CEO Bill An­der­son said that the com­pa­ny has is­sued a vol­un­tary re­call due to a man­u­fac­tur­ing is­sue. An­der­son said in cer­tain cas­es dur­ing re­li­a­bil­i­ty test­ing, it was de­ter­mined that the sep­tum, or seal on the de­liv­ery de­vice, could fail af­ter re­peat­ed dos­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER